Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Biol Chem. 2016 Dec 1;397(12):1265–1276. doi: 10.1515/hsz-2016-0177

Figure 2. Probability of overall survival and progression-free survival of patients with advanced ovarian cancer (FIGO III/IV) as stratified by KLK6, KLK8 and KLK6+KLK8 mRNA expression levels, respectively, in primary tumor tissues.

Figure 2

(A) Patients with low KLK6 mRNA expression show significantly better overall survival (Kaplan-Meier analysis, P = 0.032) (left panel) than the group of patients with high KLK6 mRNA expression, but not for progression-free survival (right panel). (B) KLK8 mRNA levels have no impact on both overall survival (left panel) and progression-free survival (right panel). (C) Patients with high KLK6 and/or high KLK8 expression (KLK6+8 high) display significantly shorter overall survival (Kaplan-Meier analysis, P = 0.048) (left panel) and progression-free survival (P = 0.042) (right panel), compared to patients with low mRNA expression levels of both KLK6 and KLK8 (KLK6+8 low). In all of the analyses, KLK6 and KLK8 mRNA levels were dichotomized into low and high by the median.